IRVINE, CA and HERSTAL, BELGIUM, May 20, 2016 – MDxHealth SA (NYSE Euronext: MDXH) (“MDxHealth”) announced today, pursuant to Article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulated market, that on May 19, 2016, 116,000 new ordinary shares were issued by MDxHealth further to the exercise of 116,000 warrants by employees and consultants of MDxHealth, for an aggregate exercise price of € 196,920.00 for all warrants. The exercised warrants were initially issued in April 2011 and May 2012.
As a result of the aforementioned exercise of warrants, the share capital of MDxHealth increased from € 36,018,550.66 to € 36,111,083.86 and the number of outstanding shares increased from 45,153,633 to 45,269,633 shares.
On the date of this press release, the total number of existing warrants (whether or not already granted or already vested) amounts to 2,087,063 warrants which (if exercised) would entitle their holders to 2,087,063 shares with voting rights. All outstanding shares have voting rights.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.
| For more information: Dr. Jan Groen, CEO MDxHealth US: +1 949 812 6979 BE: +32 4 364 20 70 info@mdxhealth.com |
|
Amber Fennell, Chris Welsh, Hendrik Thys (PR & IR) Consilium Strategic Communications UK: +44 20 3709 5701 US: +1 917 322 2571 (Rx Communications Group LLC) mdxhealth@consilium-comms.com |
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
